Group 1 - The core viewpoint of the article highlights the financial performance and market position of Lanwei Medical, indicating a decline in stock price and net profit for the recent quarter [1] - As of September 30, 2024, the number of shareholders for Lanwei Medical increased to 28,060, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - Lanwei Medical provides comprehensive solutions for the diagnostic industry, offering third-party medical testing and pathology diagnosis services, as well as in vitro diagnostic products [1] Group 2 - The latest financial report for the third quarter of 2024 shows that the company achieved a revenue of 1.32 billion yuan, representing a year-on-year increase of 3.95%, while the net profit was a loss of approximately 40.58 million yuan, a significant decline of 4,511.40% year-on-year [1] - The gross profit margin for the company stands at 21.00% [1] - The company has established a strong sales network across multiple provinces in China, particularly in Hunan and Hubei, enhancing its market share and brand recognition [1]
兰卫医学收盘下跌1.50%，最新市净率2.28，总市值39.41亿元